ホーム › 卵巣がん › ペンシルベニア › Pittsburgh
Pittsburgh、PAにおける卵巣がんの臨床試験
Pittsburghとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する30件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
被験者募集中第2/3相
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- 他3件
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
被験者募集中
- UPMC Hillman Cancer Center, Pittsburgh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
被験者募集中第1相
- Research Site, Pittsburgh
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
被験者募集中第2相
- Western Pennsylvania Gynecologic Oncology /ID# 278632, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Allegheny Health Network, Pittsburgh
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh
- Allegheny Health Network- West Penn Hospital, Pittsburgh
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
被験者募集中第2相
- University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh
- West Penn Hospital of Allegheny Health Network, Pittsburgh
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
被験者募集中第1/2相
- Allegheny Singer, Pittsburgh
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
被験者募集中第1/2相
- Research Site, Pittsburgh
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
被験者募集中第3相
- Allegheny Health Network West Penn Hospital ( Site 0099), Pittsburgh
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
被験者募集中第3相
- AHN West Penn Hospital, Pittsburgh
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- UPMC, Pittsburgh
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
被験者募集中
- Allegheny General Hospital, Pittsburgh
- UPMC-Magee Womens Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
- 他5件
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Allegheny Health Network, Pittsburgh
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
被験者募集中第2相
- 127, Pittsburgh
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
被験者募集中第2相
- Allegheny Health Network, Pittsburgh
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
被験者募集中第2相
- UPMC Magee-Women's Hospital, Pittsburgh
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
被験者募集中第1相
- Magee-Womens Research Institute / UPMC Magee Womens Hospital, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
被験者募集中第2相
- University of Pittsburgh Medical Center, Pittsburgh
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
被験者募集中第2相
- Allegheny Health Network West Penn Hospital /ID# 272267, Pittsburgh
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
被験者募集中第3相
- West Penn Hospital, Pittsburgh
- Jefferson Hospital, Jefferson Hills · 11マイル先
- Forbes Hospital, Monroeville · 11マイル先
- 他1件
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
被験者募集中第2相
- Allegheny Health Network West Penn Hospital, Pittsburgh
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
Pittsburghにおける他の研究
- 非小細胞肺癌48件の研究
- がん（全種類）41件の研究
- 乳がん39件の研究
- 大腸癌32件の研究
- 転移性癌31件の研究
- 悪性黒色腫31件の研究
- 子宮内膜がん23件の研究
- 前立腺がん23件の研究
- 肺がん23件の研究
- 頭頸部扁平上皮癌22件の研究
- 脳卒中22件の研究
- うつ病22件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。